Venturi Wealth Management LLC Raises Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Venturi Wealth Management LLC raised its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 170.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,367 shares of the medical research company's stock after buying an additional 2,751 shares during the quarter. Venturi Wealth Management LLC's holdings in Charles River Laboratories International were worth $806,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Empower Advisory Group LLC lifted its position in Charles River Laboratories International by 2.5% in the fourth quarter. Empower Advisory Group LLC now owns 275,851 shares of the medical research company's stock worth $50,922,000 after buying an additional 6,747 shares during the last quarter. AlphaCentric Advisors LLC bought a new stake in Charles River Laboratories International in the fourth quarter worth $272,000. Baillie Gifford & Co. lifted its position in Charles River Laboratories International by 10.0% in the fourth quarter. Baillie Gifford & Co. now owns 75,411 shares of the medical research company's stock worth $13,921,000 after buying an additional 6,826 shares during the last quarter. V Square Quantitative Management LLC lifted its position in Charles River Laboratories International by 12.6% in the fourth quarter. V Square Quantitative Management LLC now owns 1,084 shares of the medical research company's stock worth $200,000 after buying an additional 121 shares during the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in Charles River Laboratories International in the fourth quarter worth $335,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Up 0.5 %

Shares of Charles River Laboratories International stock traded up $0.86 during trading on Friday, hitting $163.11. 1,215,947 shares of the stock traded hands, compared to its average volume of 1,060,465. The stock's fifty day simple moving average is $173.39 and its 200 day simple moving average is $188.81. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $275.00. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a market cap of $8.34 billion, a P/E ratio of 1,087.39, a price-to-earnings-growth ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the previous year, the firm earned $2.46 earnings per share. The firm's quarterly revenue was down 1.1% compared to the same quarter last year. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 9.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on CRL shares. William Blair downgraded Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. Evercore ISI raised their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research report on Thursday, November 7th. TD Cowen lifted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research report on Monday, November 11th. Barclays decreased their target price on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a research report on Tuesday. Finally, Bank of America decreased their target price on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $195.71.

Insider Buying and Selling at Charles River Laboratories International

In related news, COO Birgit Girshick purchased 1,514 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares of the company's stock, valued at $9,064,198.54. The trade was a 2.83 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company's stock, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).